NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $13.94 +0.17 (+1.23%) Closing price 04:00 PM EasternExtended Trading$14.15 +0.21 (+1.51%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$13.55▼$14.4350-Day Range$11.43▼$15.4452-Week Range$3.78▼$15.71Volume158,846 shsAverage Volume200,721 shsMarket Capitalization$257.89 millionP/E RatioN/ADividend YieldN/APrice Target$10.81Consensus RatingModerate Buy Company Overview OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts. Read More OptimizeRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 41% of companies evaluated by MarketBeat, and ranked 458th out of 657 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -16.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -16.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOptimizeRx has a PEG Ratio of 4.59. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.60% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in OptimizeRx has recently decreased by 8.28%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.60% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in OptimizeRx has recently decreased by 8.28%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.84 News SentimentOptimizeRx has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 4 news articles for OptimizeRx this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows1 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesInsider Stock Buying Reaches US$2.54m On OptimizeRxJuly 23 at 7:44 AM | finance.yahoo.comOptimizeRx: Stock Could Rise As Profitability Is AchievedJuly 18, 2025 | seekingalpha.comWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re quietly shipping 30 tons per year from a facility outside San Antonio.July 24 at 2:00 AM | True Market Insiders (Ad)OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ETJuly 17, 2025 | globenewswire.comInvestors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three yearsJuly 4, 2025 | finance.yahoo.comOptimizeRx Corporation Appoints CEO Steve Silvestro to Board of DirectorsJune 24, 2025 | globenewswire.comCalculating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)June 18, 2025 | finance.yahoo.comSimulmedia & OptimizeRx partner to bring Micro-Neighborhood® targeting to TV & streamingJune 18, 2025 | msn.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $4.86 at the start of the year. Since then, OPRX shares have increased by 186.8% and is now trading at $13.94. How were OptimizeRx's earnings last quarter? OptimizeRx Corp. (NASDAQ:OPRX) issued its earnings results on Monday, May, 12th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.19. The business earned $21.93 million during the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a negative trailing twelve-month return on equity of 0.29% and a negative net margin of 16.33%. Read the conference call transcript. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional shareholders include Blair William & Co. IL (3.40%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh and Ellen O'connor Vos. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/12/2025Today7/24/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry COMP - SOFTWARE Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Price Target for OptimizeRx$10.81 High Price Target$16.00 Low Price Target$5.00 Potential Upside/Downside-24.3%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth4.43Net Income-$18.66 million Net Margins-16.33% Pretax Margin-17.08% Return on Equity-0.29% Return on Assets-0.20% Debt Debt-to-Equity Ratio0.25 Current Ratio2.82 Quick Ratio2.82 Sales & Book Value Annual Sales$92.13 million Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value$6.35 per share Price / Book2.25Miscellaneous Outstanding Shares18,500,000Free Float17,459,000Market Cap$264.09 million OptionableOptionable Beta1.34 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:OPRX) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.